GT Biopharma Inc (GTBP)

GT Biopharma's stock price has experienced a significant decline over the past year. Key events include the IND submission and FDA clearance for GTB-5550, participation in conferences, the release of full-year 2025 financial results, progress in the GTB-3650 Phase 1 trial, and stock price fluctuation.

The provided search results do not contain specific information regarding demand seasonality for GT Biopharma, Inc.'s products and services. Demand for its potential future products would likely be driven by medical need and clinical efficacy rather than traditional seasonal patterns.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies, operating within the Healthcare sector, specifically in the Biotechnology industry. The company's core business revolves around its Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms, designed to enhance the cancer-killing abilities of a patient's natural killer (NK) cells. Major products and product candidates include the TriKE™ Platform, GTB-3550, GTB-3650, GTB-5550, and GTB-7550.

GT Biopharma, Inc. is headquartered in San Francisco, California, United States, with a primary focus on the development and commercialization of its immuno-oncology products within the United States.

GT Biopharma's brand reputation is primarily tied to its scientific advancements and clinical trial progress in the immuno-oncology space. Positive events include the FDA clearance of IND for GTB-5550, continued progress in the GTB-3650 Phase 1 trial, and presentations at investor conferences. There is no explicit mention of negative events impacting its brand reputation, although the significant decline in stock price could indirectly affect investor sentiment.

GT Biopharma, Inc. has 43 institutional owners and shareholders, holding a total of 502,868 shares. Major institutional owners include Citadel Advisors Llc, Scientech Research LLC, and Seacrest Wealth Management, Llc. Insider ownership is reported as 0.00%.